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Key points 40 
Question Is an individualized biomechanical footwear therapy effective for reducing 41 
knee pain in people with osteoarthritis? 42 
 43 
Findings In this randomized trial that included 220 participants with knee pain due 44 
to osteoarthritis, treatment with an individualized biomechanical footwear therapy 45 
compared with control footwear resulted in a lower WOMAC pain subscore (range 0 to 46 
10), 1.3 pts vs 2.6 pts after 24 weeks, a difference that was statistically significant. 47 
 48 
Meaning Although use of biomechanical footwear compared with control footwear 49 
resulted in an improvement in knee pain at 24 weeks that was statistically significant, 50 
the difference was of uncertain clinical importance, and further research is needed to 51 
assess longer term efficacy and safety.  52 
 4 
Abstract 53 
Importance: Individually calibrated biomechanical footwear therapy may improve pain 54 
and function in people with symptomatic knee osteoarthritis, but benefits of this therapy 55 
are unclear.  56 
Objective:  To assess the effect of a biomechanical footwear therapy vs control 57 
footwear over 24 weeks.  58 
Design, Setting and Participants: Randomized, controlled, single-center superiority 59 
trial in a Swiss University hospital. Participants (N= 220) with symptomatic, 60 
radiologically confirmed knee osteoarthritis were recruited between April 20, 2015 and 61 
January 10, 2017. The last participant visit occurred on August 15, 2017. 62 
Interventions:  Participants were randomized to biomechanical footwear involving 63 
shoes with individually adjustable external convex pods attached to the outsole (n=111) 64 
or to control footwear (n=109) that had visible outsole pods that were not adjustable and 65 
did not create a convex walking surface.  66 
Main Outcomes and Measures:  The primary outcome was knee pain at 24 weeks 67 
assessed with the Western Ontario and McMaster Universities Osteoarthritis Index 68 
(WOMAC) pain subscore standardized to range from 0 (best) to 10 (worst). Secondary 69 
outcomes included WOMAC function, stiffness and global scores, all ranging from 0 70 
(best) to 10 (worst) at 24 weeks, and serious adverse events.  71 
Results:  Among 220 randomized participants (mean age 65.1 years; 104 (47.3%) 72 
women), 219 received the allocated treatment and 213 (96.8%) completed follow-up. At 73 
24 weeks, mean standardized WOMAC pain subscores improved from 4.3 to 1.3 in the 74 
intervention group, and from 4.0 to 2.6 in the control group (difference in scores at 24 75 
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weeks, -1.3; 95%-CI -1.8 to -0.9, p<0.001). Results were consistent for WOMAC 76 
function (difference -1.1; 95%-CI -1.5 to -0.7), stiffness (difference -1.4; 95%-CI -1.9 to -77 
0.9), and global scores (difference -1.2; 95%-CI -1.6 to -0.8) at 24 weeks. Three serious 78 
adverse events occurred in the experimental group compared with 9 in the control group 79 
(2.7% vs 8.3%); none were treatment related. 80 
Conclusions and Relevance:  Among participants with knee pain from osteoarthritis, 81 
use of biomechanical footwear compared with control footwear resulted in improvement 82 
in pain at 24 weeks that was statistically significant but of uncertain clinical importance. 83 
Further research would be needed to assess longer term efficacy and safety, as well as 84 
replication, before reaching conclusions about the clinical value of this device. 85 
Trial Registration:  ClinicalTrials.gov Identifier: NCT0236371286 
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INTRODUCTION 87 
Knee osteoarthritis (OA) affects approximately 265 million people worldwide, and was 88 
estimated to account for 8.3 million years lived with disability in 2017.1 The prevalence 89 
of knee OA is rising due to population aging and the increasing prevalence of obesity. 90 
Acetaminophen, non-steroidal anti-inflammatory drugs, and opioids are most commonly 91 
used to treat pain associated with OA,2 but have limited effectiveness3,4 and are 92 
associated with adverse effects.3,5,6 In the US, rates of knee replacement surgery, 93 
almost all related to OA, have been increasing, in part because of ineffective 94 
nonsurgical treatments.  95 
Biomechanical treatments for knee OA have been developed to reduce pain, 96 
improve function and, perhaps potentially to slow disease progression,7 but evidence of 97 
effectiveness is inconclusive.8,9 Two small prospective, non-randomized controlled 98 
studies suggested that an individualized biomechanical footwear system may improve 99 
pain and function in people with symptomatic knee OA.10,11 In those studies, the 100 
footwear system consisted  of shoes with 2 convex pods on the outsoles, individually 101 
calibrated based on findings from detailed, repeatedly performed gait studies. 102 
Adjustment of the location of the pods may alter limb biomechanics and reduce stress 103 
on osteoarthritic knee compartments.12–14 Walking on the convex pods results in gait 104 
alterations, which in turn is hypothesized to induce reconditioning of the neuromuscular 105 
system and improvement of improve pathological gait patterns.15 The objective of this 106 
study, the Biomechanical Therapy for Osteoarthritis of the Knee (BIOTOK) randomized 107 
trial, was to determine whether compare biomechanical footwear were more effective 108 
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thanwith control footwear for improving knee pain in participants with knee pain from 109 
osteoarthritis.  110 
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METHODS 111 
Study design and participants 112 
This was an investigator-initiated single-center randomized single-center controlled 113 
superiority clinical trial in participants with symptomatic knee OA that compared 114 
biomechanical footwear therapy using shoes with two individually calibrated convex 115 
pods on the outsoles (AposTherapy, Apos Medical Assets, New York, NY; eFigures 1 116 
and 2) with a similarly appearing control footwear therapy. The trial protocol and 117 
statistical analysis plan are in Supplement 1 and Supplement 2. 118 
We enrolled men and non-pregnant women aged ≥40 years, with symptomatic, 119 
radiologically confirmed knee OA according to the criteria of the American College of 120 
Rheumatology.16 Participants had knee pain lasting 6 months or longer, and a score ≥3 121 
at the screening visit on the Western Ontario and McMaster Universities Osteoarthritis 122 
Index (WOMAC) pain subscale17 standardized to range from 0 to 10. Exclusion criteria 123 
included history of inflammatory rheumatic disease, knee surgery in the previous 6 124 
months or planned hip or knee surgery within 24 weeks of baseline assessment, 125 
glucocorticoid knee injections in the previous three months, or a high risk of falls (see 126 
Supplement 3 for full eligibility criteria and selection of index knee). The trial was 127 
approved by the independent Research Ethics Committee of Canton Bern (KEK-BE 128 
041/215). All participants gave written informed consent. 129 
 130 
Randomization and masking 131 
Participants were randomized 1:1 to experimental footwear or control footwear using a 132 
concealed, secure web-based system. Randomization was computer-generated, 133 
 9 
blocked with randomly varied block sizes of 2 and 4, and stratified by unilateral vs 134 
bilateral knee disease and predominantly affected compartment (medial vs. lateral) in 135 
the index knee.  136 
The biomechanical footwear device consisted of 2 shoes with 2 convex 137 
adjustable rubber pods screwed to the outsole at the heel and forefoot (eFigures 1 and 138 
2 in Supplement 3). The control footwear was specifically designed by the manufacturer 139 
for this trial to have a similar appearance to the biomechanical footwear, but with pods 140 
embedded in the transparent outsole so that they were visible yet did not create a 141 
convex walking surface (eFigure 3 in Supplement 3). To avoid between-group 142 
differences in the magnitude of placebo effects  try to maintain blinding of participants, 143 
participants were kept unaware of the study design and use of control footwear. 144 
Participants were informed in a neutral manner that two different types of footwear were 145 
compared (Supplement 3). Experimental and control footwear were both presented on 146 
the manufacturer’s website, and the control footwear was described as a device with a 147 
novel design of the sole (eFigure 3 in Supplement 3).     148 
Technicians and study nurses who coordinated the clinical visits could not be 149 
blinded to treatment allocation but were asked not to disclose treatment allocation or the 150 
nature of the control footwear study component to participants. As technicians were 151 
from Israel and did not speak German, direct interaction between technicians and 152 
participants was limited, with verbal communication carried out through translating study 153 
nurses, who were independent of the manufacturer and encouraged to ensure facilitate 154 
unbiased participant interaction. The remaining study personnel performing data entry, 155 
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management and cleaning, and the statistician were blinded to the allocated 156 
intervention until all primary and secondary analyses were completed.  157 
The consent form did not state that the control footwear was intended to be 158 
ineffective (i.e. a sham).  Rather, the consent form implied that both types of shoes may 159 
have been effective.  Furthermore, the manufacturer’s website was altered to imply 160 
potentially therapeutic benefits of both the intervention and control shoe. Therefore, the 161 
trial could be considered potentially deceptive according to the International Ethical 162 
Guidelines for Health-related Research Involving Humans18—however, both 163 
experimental and control footwear included some therapeutic elements. Both were high-164 
top shoes, which provided more stability and proprioceptive input than loose shoes or 165 
sandals. Furthermore, proposed mechanisms of the experimental footwear were 166 
hypothetical at the time of initiation of this trial, and the trial was considered to entail no 167 
more than minimal risks and burdens to participants according to Article 2 of the Swiss 168 
Clinical Trials Ordinance.19 Therefore, the responsible Research Ethics Committee did 169 
not classify the trial as involving incomplete participant information (i.e., did not consider 170 
the study procedures to be ‘deceptive’) according to Article 18 of the Swiss Human 171 
Research Act.20  Nonetheless, because the trial may have been considered deceptive 172 
by some individuals, participants were debriefed after the trial was completed.   173 
Participants were advised of the rationale of the sham-controlled design, informed of 174 
differences between experimental and control footwear, and about their group 175 
allocation, and were given the opportunity to withdraw consent to participate. 176 
Supplement 3 discusses the criteria specified in the International Ethical Guidelines for 177 
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Health-related Research Involving Humans for trials that withhold information or use 178 
deception18 with respect to this trial.     179 
 180 
Procedures 181 
Participants in both groups underwent initial fitting of their assigned device by 182 
technicians at baseline and re-calibration at 4, 8, 12 and 16 weeks. The positioning of 183 
the external pods was individually adjusted on experimental devices, in accordance with 184 
gait patterns and reported pain intensity during walking, with the aim of decreasing 185 
clinically observed malalignment and reported pain intensity, and increasing gait 186 
symmetry13,14,21,22 as determined by two-dimensional computerized spatiotemporal gait 187 
analysis (Zeno walkway and PKMAS software, ProtoKinetics, Havertown, PA; 188 
Supplement 3). Participants allocated to control footwear received a simulated 189 
calibration, which mimicked calibration of the experimental footwear. Technicians, 190 
provided by the manufacturer, performed all device-related procedures (gait analyses, 191 
fitting, calibrations of experimental and control footwear).  192 
Participants were instructed to use the footwear during indoor activities for a half 193 
hour each day during the first week of the intervention, with subsequent increases of 10 194 
minutes per week on average, but were not given explicit instructions to perform specific 195 
home-based exercises. After 6 weeks, the participants were advised to use the footwear 196 
to walk outdoors. Participants were asked to stop their regular pain medication and 197 
advised that other interventions such as physical therapy should be avoided during the 198 
trial. They were permitted daily therapy as needed with acetaminophen at a maximum 199 
dose of 2 g, with amounts recorded at each visit. 200 
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 201 
Outcomes 202 
The prespecified primary outcome was knee pain at the end of treatment (24-week 203 
follow up) in the index knee, as assessed with the WOMAC pain subscore (visual 204 
analogue version) (standardized 0-10 scale, 0=best).17 The secondary outcomes 205 
prespecified in the protocol were WOMAC global score (standardized 0-10 scale, 206 
0=best), WOMAC physical function and stiffness subscores (standardized 0-10 scale, 207 
0=best) at 12 and 24 weeks follow-up; WOMAC pain subscore at 4, 8, 12 and 16 208 
weeks; the physical and mental component summary scores of the Medical Outcomes 209 
Study Short Form 36-item Health Survey (SF-36) (standardized to have a mean of 50 210 
and a standard deviation of 10 for the general population, with theoretical range 0-100, 211 
100=best)23 at 12 and 24 weeks; gait velocity, step length, and single limb support, as 212 
measured by two-dimensional computerized gait analysis when walking barefoot at 4, 8, 213 
12, 16 and 24 weeks; self-reported time spent wearing footwear per day; self-reported 214 
health care utilization; and analgesic use, as between-group differences in analgesic 215 
use could result in performance bias.24 Minimal clinically important differences were not 216 
considered when planning the trial. Other prespecified outcomes were treatment 217 
response defined as a 30% decrease in WOMAC pain from baseline and as a 50% 218 
decrease in WOMAC pain from baseline.25 Treatment response defined as a 50% 219 
decrease in WOMAC pain from baseline was not prespecified in the protocol, but was 220 
included in the statistical analysis plan. The adverse events prespecified in the protocol 221 
were falls, any adverse events, serious adverse events, dropouts, and dropouts due to 222 
adverse events (Supplement 3). WOMAC scores,17 analgesic intake, and gait analysis 223 
Formatted: Highlight
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parameters were recorded at baseline, 4, 8, 12, 16 and 24 weeks; SF-36 scores and 224 
healthcare utilization were recorded at baseline and 12 and 24 weeks. Adverse events 225 
and time spent wearing footwear were recorded at each follow-up visit. Two 226 
investigators blinded to the assigned treatment adjudicated all potential adverse events 227 
based on notes by participants and nurses, and, in case of potential serious adverse 228 
events, based on relevant medical records.  229 
 230 
Statistical analysis 231 
A sample size of 100 participants per group yielded 80% power to detect a difference of 232 
1.05 on a standardized WOMAC pain scale ranging from 0 to 10 at a two-sided alpha of 233 
0.05. The difference corresponds to a moderate effect size of 0.4 standard deviation 234 
units assuming a typical standard deviation of 2.65.4 The protocol prespecified the use 235 
of analyses of covariance for all continuous outcomes, adjusted for the outcome’s 236 
baseline values. For this approach, a sample size of 100 participants per group would 237 
yield approximately 90% power, assuming a correlation of 0.5 between baseline and 24-238 
week follow-up. Anticipating an attrition rate of 10%, the target sample size was 220 239 
participants.  240 
Continuous outcomes were analyzed using analysis of covariance adjusted for 241 
the outcome’s baseline values and variables used for stratified randomization, 242 
considering only the assessments of the index knee of each participant. Binary 243 
outcomes were analyzed using Cochran-Mantel-Haenszel tests stratified by 244 
stratification variables.26 All randomized participants were included in analyses 245 
according to their randomized allocation,27 using multiple imputation to impute missing 246 
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outcome data, using all baseline characteristics (age, sex, BMl, blood pressure, medical 247 
history, WOMAC scores, SF-36 scores, and parameters of gait analysis), outcomes at 248 
all time-points, the treatment indicator, and stratification variables to generate 20 249 
imputed datasets (Supplement 3).  250 
Pre-specified subgroup analyses of the primary outcome were performed 251 
according to the predominantly affected compartment and the presence or absence of 252 
symptomatic contralateral knee OA and accompanied by tests for interaction. A post-253 
hoc subgroup analysis was done according to WOMAC pain intensity at baseline.28 Pre-254 
specified sensitivity analyses of the primary outcome included a per-protocol analysis, a 255 
complete case analysis, adjustments for potential procedural confounders, and a linear 256 
mixed effects model to analyze all knees (i.e., index or both index and contralateral 257 
knee) with a baseline WOMAC pain subscale score of ≥3. Post-hoc sensitivity analyses 258 
of WOMAC scores, SF-36 scores and parameters of gait analyses were performed 259 
using all time points in a linear mixed-effects regression model (Supplement 3). P-260 
values and 95% confidence intervals (CIs) were two-sided, p-values ≤0.05 were 261 
considered statistically significant. Because of the potential for type 1 error due to 262 
multiple comparisons, findings for analyses of secondary outcomes should be 263 
interpreted as exploratory. Analyses were performed in R version 3.3.2,29 by an 264 
independent statistician of an academic clinical trials unit (CTU Bern, Switzerland) who 265 
was unaware of group assignment. The statistical analysis plan was finalized after 266 
completion of follow-up, but before examination of the data. Data were interpreted and 267 
conclusions formulated prior to unblinding investigators.   268 
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RESULTS 269 
Between April 20, 2015 and January 10, 2017, 220 participants were randomized: 111 270 
to the experimental footwear and 109 to control footwear (Figure 1). One participant in 271 
the experimental group refused treatment and did not receive the intervention. Seven 272 
and 13 participants, respectively, discontinued treatment during follow-up.  One hundred 273 
nine (98.2%) and 104 participants (95.4%) completed the primary outcome at 24 weeks 274 
follow-up, respectively.  After trial completion, 217 of the 220 randomized participants 275 
were reached and advised of the potential for deception in the study design. Of three 276 
participants who were not reached, one participant in the experimental group had died, 277 
and two participants in the experimental group were lost to follow-up. None of the 217 278 
participants withdrew consent after learning that the trial involved randomization to 279 
either experimental footwear or a control footwear that was expected to be ineffective.  280 
Baseline characteristics were similar between the participants randomized to 281 
each group (Table 1 and eTable 1 in Supplement 3). The study population had a mean 282 
age of 65.2 years (SD 9.3), included 47.3% females and had a mean BMI of 28.0 kg/m2 283 
(SD 4.6). Medial knee osteoarthritis was present in 90.9% and unilateral disease in 284 
67.7% of participants. The number of participants with missing data was between 0 and 285 
3 (1.4%) for baseline characteristics (eTable 2 in Supplement 3) and between 2 (0.9%) 286 
and 29 (13.2%) for outcomes (eTable 3 in Supplement 3).   287 
 288 
Primary outcome 289 
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The experimental group had a larger decrease in standardized WOMAC pain scores at 290 
24 weeks than the control group (mean scores at 24 weeks, 1.3 vs 2.6, difference -1.3; 291 
CI -1.8 to -0.9; p<0.001) (Figure 2, Table 2).  292 
 293 
Secondary outcomes 294 
The experimental group had larger declines in the secondary outcomes of WOMAC 295 
function and stiffness subscores and global score at 24 weeks (Figure 2 and Table 2). 296 
Between-group differences in velocity, step length and single limb support emerged in 297 
favor of the experimental group between 12 and 24 weeks (Table 2). The mean self-298 
reported time spent wearing the footwear at 24 weeks was 209 vs 174 minutes per day 299 
(difference 35 minutes; CI, 4 to 67 minutes). There was no statistically significant 300 
difference in the SF-36 physical component summary score between the intervention 301 
vs. the control groups (mean, 45.9 vs 44.5, difference 1.4, CI -0.5 to 3.2). There were no 302 
significant differences between change in the SF-36 mental component summary score, 303 
analgesic use, or health care between the two groups. eTable 4 in Supplement 3 304 
presents the additional prespecified secondary outcomes, types of analgesics, health 305 
care providers, corticosteroid injections, and performed or planned knee replacement 306 
surgery. eTable 5 in Supplement 3 reports the other prespecified outcomes, treatment 307 
response achieving a 30% or 50% reduction in WOMAC pain from baseline to 24 308 
weeks. Ninety-two vs 58% of participants achieved a 30% reduction (risk difference 309 
34%; 95% CI 23% to 45%), and 83% vs 42% achieved a 50% reduction (risk difference 310 
41%; 95% CI 28% to 52%) in the experimental and control groups, respectively, 311 
corresponding to numbers-needed-to-treat of 3 (95% CI 2 to 5) and 3 (95% CI 1 to 4). 312 
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Pre-specified subgroup analyses of the primary outcome according to predominantly 313 
affected compartment and symptomatic contralateral disease did not show significant 314 
treatment-by-subgroup interactions (eTable 6 in Supplement 3). Sensitivity analyses of 315 
the primary outcome, including a per-protocol analysis, a complete case analysis, 316 
adjustments for potential procedural confounders, and a linear mixed effects model to 317 
analyze all knees with a baseline WOMAC pain subscore of ≥3 were consistent with 318 
main analyses (eTables 7 to 11 in Supplement 3).  319 
 320 
Adverse events 321 
Twenty-six (23%) participants in the intervention group and 38 participants (35%) in the 322 
control group experienced an adverse event (Table 3). Three (2.7%) and 9 participants 323 
(8.3%), respectively, experienced serious adverse events. None were considered 324 
treatment related. None vs. 4 serious adverse events were musculoskeletal, 1 vs. 3 325 
were circulatory, 2 vs. 2 were in other categories, respectively (eTable 12 in 326 
Supplement 3). One or more falls occurred in 2 (1.8%) and 4 participants (3.7%), 327 
respectively; 1 participant in the control group fell while wearing the control footwear.  328 
 329 
Post-hoc analyses 330 
A post hoc subgroup analysis of the primary outcome by WOMAC pain intensity at 331 
baseline did not show significant treatment-by-subgroup interactions (eTable 6 in 332 
Supplement 3). The post-hoc use of a mixed-effects model simultaneously including all 333 
timepoints showed results similar to those of main analyses. In the mixed-effects 334 
models, there were significant differences in WOMAC pain and physical function 335 
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subscores and WOMAC global scores at 12, 16 and 24 weeks, and WOMAC stiffness 336 
subscores at 16 and 24 weeks follow-up. Significant differences in parameters of gait 337 
analysis were observed for velocity and step length at weeks 12, 16 and 24, and for 338 
single limb support at week 24 (eTable 13 in Supplement 3). eFigure 4 in Supplement 3 339 
contrasts WOMAC pain subscores with the time spent wearing the footwear over the 340 
duration of the trial. The maximal difference in time spent wearing the footwear occurred 341 
at 16 weeks, while the maximum difference in WOMAC pain scores was observed 8 342 
weeks later, at 24 weeks.   343 
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DISCUSSION 344 
In this randomized trial, a biomechanical footwear system with individually calibrated 345 
outsole convex pods was more effective than a control biomechanical footwear at 346 
reducing pain at 24 weeks in participants with knee pain from symptomatic knee OA. 347 
Results were consistent for secondary outcomes of WOMAC function and stiffness 348 
subscores and global score at 24 weeks. There were no significant differences between 349 
groups in physical and mental components of the SF-36.  350 
There are two differences between the biomechanical footwear system tested in 351 
this trial, and other biomechanical devices such as shoes9 or wedges.8 First, in this trial, 352 
the individualized calibration of proximal and distal pods of the experimental device in 353 
coronal and sagittal planes shifts the trajectory of the foot’s center of pressure, thereby 354 
specifically changing the direction of the ground reaction force vector as appropriate for 355 
each individual.12,13,30 Second, the convexity of the pods in the experimental footwear 356 
results in repetitive gait perturbation, with mild destabilization of the knee during 357 
walking, which in turn may elicit neuromuscular responses.  358 
To our knowledge, no other published randomized trials have investigated the 359 
effectiveness of this biomechanical footwear system in people with symptomatic knee 360 
OA. Of six published clinical studies,10,11,15,31–33 four were uncontrolled studies 361 
conducted by the manufacturer,15,31–33 the remaining two were prospective and 362 
controlled, but non-randomized.10,11 The most rigorous investigation was a prospective 363 
non-randomized controlled study in 57 participants with symptomatic knee OA,10 which 364 
found improved pain and function with the biomechanical footwear system as compared 365 
to a control shoe. However, the difference between groups in WOMAC pain subscores 366 
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at 8 weeks was not consistent with the negative 8-week resultestimate near null in the 367 
current study. The reason for this difference is unclear, but may be due to lack of 368 
randomization in the prior trial.  369 
 370 
Limitations 371 
This study has several limitations. First, the appearance of the experimental footwear 372 
and control footwear was different. To overcome this limitation and minimize the 373 
likelihood that participants would correctly guess that they were not receiving the active 374 
intervention, participants were kept unaware that the control shoe was not expected to 375 
have therapeutic benefits. Participants were informed in a neutral fashion that two 376 
different types of footwear were compared. The manufacturer’s website described the 377 
control footwear as a device with a novel design of the sole, and participants allocated 378 
to the control group received a simulated calibration that mimicked the actual 379 
calibration. Second, the use of a blinding index34 to determine success of blinding was 380 
not performed, because  such an index assumes indistinguishable interventions. Third, 381 
the self-reported time per day wearing the footwear was longer in the experimental 382 
group than in the control group.  It is possible that the greater benefit in the intervention 383 
group was due to longer wear time. Fourth, analgesic treatment for pain was allowed 384 
during the trial, but rates of analgesic use did not differ between groups. Fifth, it was not 385 
possible to explore changes in knee adduction moments using three-dimensional gait 386 
analyses. Sixth, the trial was conducted in a single center, potentially limiting 387 
generalizability. Seventh, between-group differences occurred only late during follow-up 388 
and were smaller than the observed within-group change from baseline in the control 389 
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group. Therefore, the clinical importance of these findings remains uncertain. Eighth, 390 
the findings from this trial are not generalizable to people at high risk of falls, as these 391 
individuals were ineligible. Ninth, the findings are not generalizable to people with 392 
severe knee pain, as these individuals were underrepresented in the trial.  393 
 394 
Conclusions 395 
Among participants with knee pain from osteoarthritis, use of biomechanical footwear 396 
compared with control footwear resulted in an improvement in pain at 24 weeks that 397 
was statistically significant but of uncertain clinical importance. Further research would 398 
be needed to assess longer term efficacy and safety, as well as replication, before 399 
reaching conclusions about the clinical value of this device.  400 
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Figures 553 
Figure 1. Participant recruitment, randomization, and follow-up 554 
NOTE- THERE APPEARS TO BE A MATH ERROR IN FIGURE 1- “NOT ELIGIBLE” 555 
SHOULD BE 455 (NOT 457). 556 
Definitions for WOMAC scores and Kellgren-Lawrence grades can be found in footnote to Table 1. 557 
STEADI, Stopping Elderly Accidents, Deaths, and Injuries score; STEADI score of 4 or greater at the 558 
screening visit was considered to indicate a high risk of falls. 559 
*The 2 and 5 participants without primary outcome data all also discontinued treatment and were 560 
therefore counted as part of the 7 and 13 participants reported to have discontinued treatment.    561 
 28 
Figure 2. WOMAC scores during the 24-week follow up period 562 
Box and whisker plots, with the box representing median and interquartile range, whiskers the most 563 
extreme values within 1.5 times of the interquartile range beyond the 25
th
 and 75
th
 percentile, and circles 564 
the more extreme values. Panel A shows the pain subscores (primary outcome) of the Western Ontario 565 
and McMaster Universities Osteoarthritis Index (WOMAC). Panels B and C display the WOMAC physical 566 
function and stiffness subscores, respectively. Panel D shows the WOMAC global scores. Definitions for 567 
WOMAC scores can be found in footnote to Table 1.  568 
  569 
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Tables 570 
Table 1. Participant Characteristics at Baseline 
Characteristic 
Biomechanical 
Footwear  
(N=111) 
Control  
Footwear  
 (N=109) 
Sex — no. (%) 
      Female 
      Male 
  
51 (45.9) 
60   (54.1) 
  
53 (48.6) 
56   (51.4) 
Age yr — mean (SD)  65.3 (9.2)  65.0 (9.3) 
Weight  kg — mean (SD)  80.6 (15.7)  82.7 (14.2) 
Height  cm — mean (SD)  170.4 (8.6)  170.9 (8.2) 
Body mass index
a
 kg/m
2 
— mean (SD)  27.7 (4.8)  28.3 (4.3) 
History of meniscal resection — no. (%)  55 (49.5)  50 (45.9) 
Knee joint effusion — no. (%)  18 (16.2)  17 (15.6) 
Kellgren-Lawrence grade
b
 — no. (%)   
 2  33 (29.7)  36 (33.0) 
 3  50 (45.9)  46 (41.4) 
 4  28 (25.2)  27 (24.8) 
Medial knee osteoarthritis — no. (%)  101 (91.0)  99 (90.8) 
WOMAC scores
c 
— mean (SD)
 
  
 Pain  4.3 (1.8)  4.0 (2.0) 
 Physical function  3.5 (1.8)  3.4 (1.8) 
 Stiffness  5.0 (2.4)  4.4 (2.4) 
 Global  3.8 (1.7)  3.6 (1.7) 
SF-36 scores
d 
— mean (SD)
 
  
 Physical component  40.4 (7.1)  40.3 (6.2) 
 Mental component  57.0 (7.4)  56.4 (8.8) 
Used analgesics in the past week — no. (%)  44 (40)  35 (32) 
 Continuous variables are summarized as mean and standard deviation (SD). Knee-related 
characteristics are with regard to the index knee. Percentages may not total 100 because of 
rounding. For additional baseline characteristics, see eTable 1 in Supplement 3. 
a
 The body-mass index is the weight in kilograms divided by the square of the height in meters. 
b
  Kellgren-Lawrence grades range from 0 to 4; a grade ≥2 indicates definite osteoarthritis on 
anteroposterior weight-bearing radiograph; grade 2, definite osteophytes and possible joint space 
narrowing; grade 3, multiple osteophytes, definite joint space narrowing, sclerosis and possible bony 
deformity; grade 4, large osteophytes, marked JSN, severe sclerosis and definite bony deformity 
c
 WOMAC, Western Ontario McMaster Universities Osteoarthritis Index, a self-administered 
questionnaire including 5 questions on pain, 17 questions on physical function and 2 questions on 
stiffness; all 4 composite scores were standardized to range from 0 to 10 (0, no symptoms; 10, 
extreme symptoms). For the WOMAC pain subscore, scores ≤4 indicate mild pain, scores >4 to ≤7 
moderate pain, and scores >7 severe pain.
28
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d
 The 36-Item Short-Form Health Survey (SF-36) comprises physical and mental component summary 
scores. Each component score having a mean of 50 and standard deviation of 10 for the general 
population, with higher summary scores indicating better health. 
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Table 2. Primary and Secondary Outcomes  
Outcome 
Biomechanical 
Footwear  
(N=111) 
Control  
Footwear  
 (N=109) 
Mean or risk 
difference 
 (95% CI) 
P Value 
Primary outcome     
WOMAC Pain at 24 weeks  1.3 (1.3)  2.6 (2.0)  -1.3 (-1.8 to -0.9) < 0.001 
Secondary outcomes     
WOMAC Pain     
 4 weeks  3.2 (1.9)  3.4 (2.0)  -0.4 (-0.9 to 0.0) 0.04 
 8 weeks  2.5 (1.6)  2.6 (1.8)  -0.3 (-0.7 to 0.1) 0.19 
 12 weeks  2.3 (1.7)  2.6 (2.1)  -0.5 (-0.9 to -0.1) 0.03 
 16 weeks  2.0 (1.7)  2.4 (1.9)  -0.5 (-1.0 to -0.1) 0.02 
WOMAC Physical function     
 12 weeks  2.1 (1.4)  2.5 (2.0)  -0.5 (-0.9 to -0.1) 0.01 
 24 weeks  1.4 (1.2)  2.4 (1.8)  -1.1 (-1.5 to -0.7) < 0.001 
WOMAC Stiffness     
 12 weeks  2.9 (2.0)  2.8 (2.3)  -0.3 (-0.8 to 0.2) 0.25 
 24 weeks  1.6 (1.5)  2.8 (2.2)  -1.4 (-1.9 to -0.9) < 0.001 
WOMAC Global     
 12 weeks  2.2 (1.4)  2.5 (2.0)  -0.5 (-0.9 to -0.1) 0.25 
 24 weeks  1.4 (1.2)  2.5 (1.8)  -1.2 (-1.6 to -0.8) < 0.001 
SF-36 Physical component     
 12 weeks  43.1 (7.6)  43.8 (7.3)  -0.7 (-2.4 to 0.9) 0.39 
 24 weeks  45.9 (7.4)  44.5 (8.0)  1.4 (-0.5 to 3.2) 0.14 
SF-36 Mental component     
 12 weeks  57.1 (7.0)  56.2 (8.9)  0.6 (-1.2 to 2.4) 0.51 
 24 weeks  56.8 (6.7)  56.0 (9.0)  0.5 (-1.4 to 2.4) 0.59 
Any health care use up to 24 
weeks
a
 — no. (%) 
 41 (37.3)  29 (27.0) 10.3% (-2.5 to 22.7%) 0.10 
Any analgesic use at 24 weeks 
— no. (%) 
 45 (40.5)  49 (45.0)  -4.4% (-17.5 to 8.8%) 0.51 
Analgesic dose in those with 
analgesic use at 24 weeks
b 
(N=45) 
875 (250-2569) 
(N=49) 
875 (250, 2500) 
  
 0 (-1038 to 1038) 
 
1.00 
Gait analysis (barefoot)     
Velocity  (cm/sec) — mean (SD)     
 4 weeks  107.7 (16.1)  109.9 (17.7)   1.1 (-1.8 to 4.0) 0.44 
Outcome Biomechanical 
Footwear  
Control  
Footwear  
Mean or risk 
difference 
P Value 
 32 
(N=111)  (N=109)  (95% CI) 
 8 weeks  111.9 (16.8)  112.2 (19.5)   2.9 (-0.7 to 6.4) 0.12 
 12 weeks  114.0 (17.3)  112.8 (19.3)   4.3 (0.7 to 7.9) 0.02 
 16 weeks  114.3 (18.0)  113.2 (19.1)   4.0 (-0.1 to 8.2) 0.06 
 24 weeks  115.7 (17.1)  114.8 (19.2)   3.6 (-0.4 to 7.6) 0.08 
Step length, index knee (cm) — mean (SD)    
 4 weeks  60.4 (6.5)  60.4 (7.6)   0.7 (-0.3 to 1.6) 0.16 
 8 weeks  61.3 (6.9)  61.1 (8.3)   0.9 (-0.3 to 2.1) 0.15 
 12 weeks  61.8 (7.0)  60.9 (8.3)   1.5 (0.3 to 2.8) 0.02 
 16 weeks  62.3 (7.1)  61.2 (8.0)   1.6 (0.2 to 3.1) 0.03 
 24 weeks  62.5 (6.9)  61.6 (8.2)   1.4 (-0.1 to 3.0) 0.07 
Single limb support, index knee (% of gait cycle) — mean (SD) 
 4 weeks  37.0 (1.7)  37.0 (1.9)   0.1 (-0.2 to 0.4) 0.39 
 8 weeks  37.3 (1.7)  37.3 (1.9)   0.1 (-0.2 to 0.4) 0.59 
 12 weeks  37.4 (1.7)  37.3 (1.9)   0.3 (0.0 to 0.6) 0.09 
 16 weeks  37.4 (1.6)  37.4 (1.8)   0.1 (-0.2 to 0.5) 0.43 
 24 weeks  37.5 (1.5)  37.3 (2.0)   0.3 (0.0 to 0.7) 0.07 
Time spent wearing footwear (min/d during the past week) — mean (SD) 
 4 weeks  70.3 (48.6)  58.1 (34.2)   12.6 (1.4 to 23.8) 0.03 
 8 weeks  129.3 (60.8)  98.9 (45.2)   30.4 (15.9 to 44.9) < 0.001 
 12 weeks  176.7 (82.3)  133.3 (66.1)   43.4 (23.0 to 63.8) < 0.001 
 16 weeks  207.8 (90.0)  146.7 (99.2)   61.2 (35.1 to 87.3) < 0.001 
 24 weeks  209.2 (102.9)  173.5 (122.9)   35.4 (4.2 to 66.6) 0.03 
 Continuous outcomes are summarized within group as mean (SD) and were analyzed at each time 
point using a linear regression model adjusted for the outcome’s baseline values and stratification 
variables, and considering only the assessments of the index knee of each participant. Refer to 
footnotes of Table 1 for definitions of WOMAC and SF-36 scales. 
 For additional secondary outcomes, see eTables 4 and 5 in Supplement 3. Mantel-Haenszel risk 
differences were adjusted for the two stratification factors (medial or lateral osteoarthritis status, and 
unilateral or bilateral knee disease at randomization). 
a
 Includes any self-reported visits to a primary care physician, rheumatologist, orthopedic surgeon, 
physiotherapist, occupational therapist, complementary or alternative health care practitioner, and 
community nurse.  
b
 Analgesic dose in participants in experimental and control groups who reported any analgesic use at 
24 weeks, expressed as acetaminophen equivalence dose in mg per day and summarized within 
groups as median with interquartile range and difference in medians between groups with 95% CI. 
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Table 3. Adverse Events 
Event 
Biomechanical 
Footwear Group 
(N=111) 
Control Footwear 
Group 
 (N=109) 
Any adverse events  26 (23.4)  38 (34.9) 
Minor adverse events  23 (20.7)  30 (27.5) 
 Musculoskeletal  15 (13.5)  21 (19.3) 
  Knee pain or swelling
a 
 2 (1.8)  3 (2.8) 
  Low back pain  5 (4.5)  5 (4.5) 
  Hip pain  5 (4.5)  3 (2.8) 
  Foot pain  2 (1.8)  3 (2.8) 
  Other  3 (2.7)  8 (7.3) 
 Injury  6 (5.4)  9 (8.3) 
  Ankle sprain  2 (1.8)  1 (0.9) 
  Fall
b 
 2 (1.8)  4 (3.7) 
  Other  2 (1.8)  4 (3.7) 
 Genitourinary  2 (1.8)  2 (1.8) 
 Circulatory  1 (0.9)  1 (0.9) 
 Nervous system  0  2 (1.8) 
 Eye  0  1 (0.9) 
 Respiratory system  1 (0.9)  0 
 Digestive system  1 (0.9)  0 
Serious adverse events
c 
 3 (2.7)  9 (8.3) 
 Musculoskeletal  0  4 (3.7) 
  Total hip or knee replacement surgery  0  3 (2.8) 
  Low back pain
d 
 0  1 (0.9) 
 Circulatory  1 (0.9)  3 (2.8) 
  Coronary heart disease
e 
 1 (0.9)  2 (1.8) 
  Other  0  1 (0.9) 
 Genitourinary  1 (0.9)  0 
 Eye  0  1 (0.9) 
 Digestive system  1 (0.9)  1 (0.9) 
 Presented are numbers of participants who experienced a specific type of event and percentages. 
Adverse event categories correspond to ICD 10 chapters and are summarized as clinical 
subcategories if at least 3 participants experienced a specific type of event. 
a
  Corresponds to local adverse events as prespecified in the protocol.  
b
 Corresponds to adverse events due to a fall, as prespecified in the statistical analysis plan. One 
participant in the control footwear group experienced a fall while wearing the study footwear. 
c
 Serious adverse events were defined as events resulting in hospitalization, prolongation of 
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hospitalization, persistent or significant disability, congenital abnormality or birth defects of offspring, 
life-threatening events, or death. 
d
 One participant in the control footwear group with lumbar disc herniation surgery. 
e
 One participant in the biomechanical footwear group with acute myocardial infarction. 
 571 
697 Patients assessed for eligibility
477 Not randomized
457 Not eligible
274 WOMAC pain <3 on standardized 0-10 scale
71 Previous knee replacement
32 Previous osteotomy
15 History of inflammatory rheumatic disease
10 Planned hip or knee surgery within 24 weeks
8 Kellgren-Lawrence grade <2
3 High risk of falling (STEADI score >4)
3 Fibromyalgia
4 Less than 40 years of age
5 Unable to come to treatment centre
5 History of knee pain shorter than 6 months
25 Other reasons
22 Did not consent
22 Lost interest in participating
220 Randomized
111 Allocated to biomechanical footwear
110 Received allocated treatment
1 Did not receive allocated treatment
1 Refused treatment 
109 Allocated to control footwear
109 Received allocated control footwear
109 With primary outcome data 
2 Without primary outcome data
2 Refused follow-up
2 Unwilling, no further reason indicated
7 Discontinued treatment*
2 No improvement of symptoms
2 Worsening of symptoms
2 Unwilling, no further reason indicated
1 Adverse event
104 With primary outcome data
5 Without primary outcome data
4 Refused follow-up 
1 No improvement of symptoms 
1 Worsening of symptoms
1 Total knee replacement
1 Unwilling, no further reason indicated
1 Lost to follow-up
13 Discontinued treatment*
5 No improvement of symptoms
3 Worsening of symptoms
2 Total knee replacement 
1 Total hip replacement
1 Unwilling, no further reason indicated
1 Lost to follow-up, no reason available
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